Tempus AI, Inc. (TEM)

NASDAQ: TEM · Real-Time Price · USD
49.86
+0.39 (0.79%)
At close: May 8, 2026, 4:00 PM EDT
49.77
-0.09 (-0.18%)
After-hours: May 8, 2026, 7:59 PM EDT
Market Cap8.95B -3.3%
Revenue (ttm)1.36B +69.8%
Net Income-302.91M
EPS-1.72
Shares Out 179.56M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume11,691,015
Open49.35
Previous Close49.47
Day's Range46.75 - 49.89
52-Week Range41.73 - 104.32
Betan/a
AnalystsBuy
Price Target71.69 (+43.78%)
Earnings DateMay 5, 2026

About TEM

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]

Sector Healthcare
IPO Date Jun 14, 2024
Employees 3,800
Stock Exchange NASDAQ
Ticker Symbol TEM
Full Company Profile

Financial Performance

In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.

Financial Statements

Analyst Summary

According to 13 analysts, the average rating for TEM stock is "Buy." The 12-month stock price target is $71.69, which is an increase of 43.78% from the latest price.

Price Target
$71.69
(43.78% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $400....

2 days ago - Business Wire

Tempus AI announces proposed convertible senior notes offering

Tempus AI (TEM) announced its intent to offer, subject to market conditions and other factors, $350.0 million aggregate principal amount of Convertible Senior Notes due in 2032 in a private

3 days ago - TheFly

Cathie Wood’s ARK Investment buys 146K shares of Tempus AI today

20:02 EDT Cathie Wood’s ARK Investment buys 146K shares of Tempus AI (TEM) today

3 days ago - TheFly

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer,...

3 days ago - Business Wire

Tempus AI price target lowered to $59 from $68 at Baird

Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Tempus AI (TEM) to $59 from $68 and keeps an Outperform rating on the shares. The firm updated its

3 days ago - TheFly

Tempus AI price target raised to $68 from $65 at TD Cowen

TD Cowen raised the firm’s price target on Tempus AI (TEM) to $68 from $65 and keeps a Buy rating on the shares. The firm said its strong growth was

3 days ago - TheFly

Lucent Diagnostics announces collaboration with Tempus AI

Lucent Diagnostics, a brand of Quanterix Corporation (QTRX), announced a collaboration with Tempus AI (TEM) to broaden access to a novel blood-based biomarker panel designed to improve detection accur...

Other symbols: QTRX
3 days ago - TheFly

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading ...

Other symbols: QTRX
4 days ago - Business Wire

Tempus AI reports Q1 adjusted EPS (13c), consensus (20c)

Reports Q1 revenue $348.1M, consensus $345.44M. “Our strong financial and operational performance this quarter underscores the accelerating demand for our AI-driven diagnostic platform and the immense...

4 days ago - TheFly

Tempus AI raises FY26 revenue view to $1.59B-$1.6B from $1.59B, consensus $1.59B

Backs FY26 adjusted EBITDA view roughly $65M.

4 days ago - TheFly

Tempus AI Earnings Call Transcript: Q1 2026

Revenue grew 36% year-over-year to $348.1 million, led by strong oncology and data businesses. Guidance was raised to $1.59–$1.6 billion in revenue and $65 million adjusted EBITDA for 2026, with robust growth in strategic pharma collaborations and improving cash flow expected.

4 days ago - Transcripts

Tempus Reports First Quarter 2026 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...

4 days ago - Business Wire

Tempus to Host Inaugural Investor Day on May 29, 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the company will host an Investor Day on Fr...

11 days ago - Business Wire

Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, today announced it has been nam...

12 days ago - Business Wire

Tempus, USC announce strategic collaboration to accelerate precision medicine

Tempus AI (TEM) and Keck School of Medicine of USC and Keck Medicine of USC announced a multi-faceted collaboration aimed at advancing patient care and accelerating research through the power

17 days ago - TheFly

Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC,...

17 days ago - Business Wire

Tempus to Report First Quarter 2026 Financial Results on May 5

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the first q...

19 days ago - Business Wire

Tempus AI, Predicta Biosciences announces expansion of GenoPredicta

Tempus AI (TEM) and Predicta Biosciences announced the commercial expansion of a co-branded whole-genome sequencing, WGS, assay, currently known as GenoPredicta, intended for the comprehensive genomic...

25 days ago - TheFly

Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developin...

25 days ago - Business Wire

Tempus AI Transcript: 25th Annual Needham Virtual Healthcare Conference

The session highlighted strong growth in diagnostics, especially oncology, and robust expansion in the data business with over $1.1 billion in TCV and new strategic collaborations. Ongoing investments in AI applications and platform tools, along with a disciplined capital allocation strategy, position the company for continued growth.

25 days ago - Transcripts

Tempus AI announces 31 abstracts for presentation at AACR annual meeting

Tempus AI (TEM) announced the acceptance of 31 abstracts-including one oral presentation-for the American Association for Cancer Research Annual Meeting 2026 taking place April 17-22 in San Diego. Tem...

26 days ago - TheFly

Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts—including one ora...

26 days ago - Business Wire

tempus AI Inc Class A call volume above normal and directionally bullish

Bullish option flow detected in tempus AI (TEM) Inc Class A with 14,076 calls trading, 1.3x expected, and implied vol increasing over 1 point to 75.75%. May-26 50 calls and

26 days ago - TheFly

Tempus AI launches automated ‘Active Follow-Up’ service

Tempus AI (TEM) announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an “active follow-up” track. This integrated workflow ...

27 days ago - TheFly

Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update servi...

27 days ago - Business Wire